Published in Circulation on February 05, 2007
A Study Of The Usage Of Statins In A Community Heart Failure Population | NCT00795912
Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol (2011) 3.74
Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol (2012) 2.03
Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. JACC Cardiovasc Imaging (2013) 1.65
Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol (2012) 1.59
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
MicroRNAs and cardiovascular diseases. FEBS J (2011) 1.41
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models. Am J Physiol Heart Circ Physiol (2009) 1.33
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail (2009) 1.27
Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res (2012) 1.25
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson (2012) 1.17
Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology (2009) 1.16
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail (2009) 1.12
Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. Am Heart J (2010) 1.07
Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev (2010) 1.05
Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc (2012) 1.04
Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res (2014) 1.03
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Apoptosis and fibrosis are early features of heart failure in an animal model of metabolic cardiomyopathy. Int J Exp Pathol (2009) 0.96
Use of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes). Comp Med (2010) 0.96
Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail (2009) 0.95
Decreased cardiac functional reserve in heart failure with preserved systolic function. J Card Fail (2010) 0.95
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg (2011) 0.90
Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol (2008) 0.89
Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res (2011) 0.89
Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration. Int J Mol Sci (2014) 0.89
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLoS One (2013) 0.86
New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group. Circulation (2014) 0.86
T1 mapping: characterisation of myocardial interstitial space. Insights Imaging (2014) 0.86
Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension. Sci Rep (2015) 0.84
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail (2012) 0.83
Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab (2012) 0.82
MR relaxometry and perfusion of the myocardium in spontaneously hypertensive rat: correlation with histopathology and effect of anti-hypertensive therapy. Eur Radiol (2013) 0.81
Integrated Glycoprotein Immobilization Method for Glycopeptide and Glycan Analysis of Cardiac Hypertrophy. Anal Chem (2015) 0.81
Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels (2009) 0.81
Current applications and Future Needs for Biomarkers in Pediatric Cardiomyopathy and Heart Failure: Summary From The Second International Conference On Pediatric Cardiomyopathy. Prog Pediatr Cardiol (2011) 0.81
Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med (2009) 0.81
Imaging in hypertensive heart disease. Expert Rev Cardiovasc Ther (2011) 0.81
Three-dimensional cardiac computational modelling: methods, features and applications. Biomed Eng Online (2015) 0.80
MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study. ISRN Cardiol (2012) 0.80
Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol (2009) 0.80
3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. PLoS One (2011) 0.80
Fibrosis assessment by integrated backscatter and its relationship with longitudinal deformation and diastolic function in heart failure with preserved ejection fraction. Int J Cardiovasc Imaging (2016) 0.79
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79
Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease. PLoS One (2014) 0.79
Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc (2014) 0.79
Effects of low-frequency noise on cardiac collagen and cardiomyocyte ultrastructure: an immunohistochemical and electron microscopy study. Int J Clin Exp Pathol (2013) 0.79
Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. J Saudi Heart Assoc (2012) 0.79
Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One (2012) 0.79
Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. Am J Physiol Cell Physiol (2015) 0.79
Chemoenzymatic method for glycomics: Isolation, identification, and quantitation. Proteomics (2015) 0.78
Diastolic dysfunction. Circ J (2015) 0.78
Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.78
Cholinergic activity as a new target in diseases of the heart. Mol Med (2015) 0.78
Cardiac extracellular matrix proteomics: Challenges, techniques, and clinical implications. Proteomics Clin Appl (2015) 0.77
Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. Am J Physiol Endocrinol Metab (2016) 0.77
Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. J Mol Histol (2013) 0.77
Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson (2016) 0.76
Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction. Heart Vessels (2016) 0.76
TNAP: a new player in cardiac fibrosis? Focus on "Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts". Am J Physiol Cell Physiol (2015) 0.76
Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J (2009) 0.75
T1 mapping in children and young adults with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2016) 0.75
The pathophysiology of diastolic heart failure. F1000 Biol Rep (2010) 0.75
A Novel Integrated Score Index of Echocardiographic Indices for the Evaluation of Left Ventricular Diastolic Function. PLoS One (2015) 0.75
Cardiac aging and heart disease in humans. Biophys Rev (2017) 0.75
Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia. Front Physiol (2017) 0.75
Associates of an elevated natriuretic peptide level in stable heart failure patients: implications for targeted management. ScientificWorldJournal (2013) 0.75
Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis. Am J Physiol Heart Circ Physiol (2016) 0.75
The association among MDCT-derived three-dimensional visceral adiposities on cardiac diastology and dyssynchrony in asymptomatic population. BMC Cardiovasc Disord (2015) 0.75
BNIP3L promotes cardiac fibrosis in cardiac fibroblasts through [Ca(2+)]i-TGF-β-Smad2/3 pathway. Sci Rep (2017) 0.75
Skeletal Myoblast Cell Sheet Implantation Ameliorates Both Systolic and Diastolic Cardiac Performance in Canine Dilated Cardiomyopathy Model. Transplantation (2016) 0.75
The N-terminal propeptide of type III procollagen in patients with acute coronary syndrome: a link between left ventricular end-diastolic pressure and cardiovascular events. PLoS One (2015) 0.75
Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout. Kidney Int (2016) 0.75
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Curr Hypertens Rep (2017) 0.75
Serum carboxy-terminal telopeptide of type I collagen (I-CTP) is predictive of clinical outcome in peripheral artery disease patients following endovascular therapy. Heart Vessels (2016) 0.75
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA (2013) 4.17
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A (2001) 3.29
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity (2007) 1.73
Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther (2011) 1.58
Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease. Hum Mutat (2006) 1.53
Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun (2006) 1.47
Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population? Circ Heart Fail (2014) 1.40
A comparative study of the palliative care needs of heart failure and cancer patients. Eur J Heart Fail (2009) 1.37
The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol (2009) 1.25
Epigenetics, the epicenter of the hypoxic response. Epigenetics (2010) 1.25
MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail (2015) 1.24
Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet (2009) 1.21
The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2013) 1.17
IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A (2013) 1.16
Heart failure management programs: can we afford to ignore the inpatient phase of care? J Card Fail (2003) 1.12
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail (2009) 1.12
European Society of Cardiology Heart Failure Association Standards for delivering heart failure care. Eur J Heart Fail (2010) 1.09
Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet (2010) 1.08
Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med (2002) 1.07
Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors (2009) 1.04
Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J Immunol (2008) 1.04
A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol (2008) 1.04
Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil (2006) 1.04
The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail (2007) 1.02
Imbalance in the expression of CXC chemokines correlates with bronchoalveolar lavage fluid angiogenic activity and procollagen levels in acute respiratory distress syndrome. J Immunol (2002) 0.99
The SERPINE2 gene and chronic obstructive pulmonary disease. Am J Hum Genet (2006) 0.99
Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. Am J Respir Crit Care Med (2005) 0.98
Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis. Am J Respir Crit Care Med (2012) 0.97
Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail (2008) 0.96
Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail (2005) 0.96
Quality of life predicts outcome in a heart failure disease management program. Int J Cardiol (2008) 0.94
Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail (2007) 0.94
Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail (2008) 0.93
The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet (2011) 0.93
Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. J Card Fail (2002) 0.90
The persistence of adolescent binge drinking into adulthood: findings from a 15-year prospective cohort study. BMJ Open (2013) 0.89
Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. Biochim Biophys Acta (2014) 0.89
Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med (2013) 0.88
Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg (2003) 0.88
The validity of the MacNew Quality of Life in heart disease questionnaire. Health Qual Life Outcomes (2004) 0.88
Multidsciplinary heart failure management and end of life care. Curr Opin Support Palliat Care (2011) 0.86
Climate change and the decline of a once common bird. Ecol Evol (2012) 0.86
Nuclear transcription of long hairpin RNA triggers innate immune responses. J Interferon Cytokine Res (2007) 0.83
Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide. J Cardiovasc Transl Res (2013) 0.83
Progression of preserved systolic function heart failure to systolic dysfunction -- a natural history study. Int J Cardiol (2006) 0.83
The value of level III clearance in patients with axillary and sentinel node positive breast cancer. Ann Surg (2009) 0.81
Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail (2004) 0.80
Airway nitric oxide output is reduced in bronchiectasis. Respir Med (2007) 0.80
Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail (2011) 0.79
Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. J Card Fail (2007) 0.79
Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One (2012) 0.79
Treatment of anaemia in chronic heart failure--optimal approach still unclear. Eur Heart J (2007) 0.78
Quantification of mitral regurgitation on cardiac computed tomography: comparison with qualitative and quantitative echocardiographic parameters. J Comput Assist Tomogr (2011) 0.78
Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide. Congest Heart Fail (2008) 0.78
Adolescent depressive symptoms and subsequent pregnancy, pregnancy completion and pregnancy termination in young adulthood: findings from the victorian adolescent health cohort study. J Pediatr Adolesc Gynecol (2011) 0.77
Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol (2009) 0.77
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opin Ther Targets (2014) 0.77
Role of proteomics in the investigation of pulmonary fibrosis. Expert Rev Proteomics (2007) 0.77
Specialist nurse supervised in-hospital titration to target dose ACE inhibitor--is it safe and feasible in a community heart failure population? Eur J Cardiovasc Nurs (2003) 0.77
Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther (2011) 0.77
Proteomics and the lung: Analysis of bronchoalveolar lavage fluid. Proteomics Clin Appl (2009) 0.76
Paul Eugen Bleuler and the origin of the term schizophrenia (SCHIZOPRENIEGRUPPE). Indian J Psychiatry (2012) 0.76
Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. Eur J Heart Fail (2007) 0.76